Navigation Links
Conatus Pharmaceuticals Appoints Anthony W. Fox, MD, Ph.D., as Chief Medical Officer
Date:3/25/2008

SAN DIEGO, March 25 /PRNewswire/ -- Conatus Pharmaceuticals Inc. today announced the appointment of Anthony "Tony" W. Fox as part-time Chief Medical Officer to oversee the recently initiated Phase 2 clinical trial of CTS-1027 in Hepatitis C virus-infected patients as well as assisting in the development of the longer-term clinical development plans.

Tony is a pharmaceutical physician with more than 20 years in the industry. Previous industrial positions have been at Procter and Gamble, Glaxo Inc. (Imitrex (R), Ultiva(R), Amerge(R)), and with small companies. Formerly, Tony was President of the whole of EBD Group, and continues now as President of EBD Consulting Inc., (Carlsbad, CA, and Munich, Germany). Among his current professional affiliations are the American College of Clinical Pharmacology, the American Society of Pharmacology and Experimental Therapeutics, and the Society of Apothecaries of London. He is a Fellow of the Institute of Biology and the Royal College of Physicians, as well as of the latter's Faculty of Pharmaceutical Medicine. Tony's numerous publications span industrial, pharmacological, regulatory, and experimental medicine areas. He co-edits "Principles and Practice of Pharmaceutical Medicine" (John Wiley and Son, second edition), which is a major international textbook in its field.

"Tony fills a critical position at Conatus," said Steven J. Mento, Ph.D., President and CEO, of Conatus. "He brings significant scientific and management experience and will be of strategic value as Conatus moves forward with the development of drug candidates to treat diseases such as hepatitis where abnormal inflammation plays a key role."

"This was an opportunity to focus on translating a well-known biological mechanism, with a well-characterized phase 2 compound, into a truly innovative area of medicine. It was also an invitation to join a team whom I already knew to be really sound, and has already achieved hard endpoints," said Dr. Fox.

Conatus Pharmaceuticals Inc. is a privately-held specialty pharmaceutical company engaged in the development of innovative human therapeutics to treat liver disease. Chronic liver disease affects millions of people worldwide and can be caused by many different conditions or "insults" to the liver including viral infection, obesity, chronic alcohol abuse or autoimmune diseases. Conatus was founded by the executive management team of Idun Pharmaceuticals in July 2005 following the successful sale of Idun to Pfizer. For additional information, please visit http://www.conatuspharma.com.


'/>"/>
SOURCE Conatus Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
3. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
4. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
5. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
6. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
8. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
9. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
10. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
11. Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... , ... October 13, 2017 , ... Many families have ... many long-term care insurance companies have a waiver for care if the client has ... period, when the family pays for care, is often waived, so the benefits from ...
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House ... most popular and least understood books in the Holy Scriptures, Revelation. The Book of ... baffled scholars for centuries. Many have tossed it off as mere rubbish, but Yisrayl ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... “America On ... Christian identity. “America On The Brink” is the creation of published author, William ... several great-grandchildren. As a WWII veteran, he spent thirty years in the Navy. ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has ... today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every formula ... the highest standard. , These products are also: Gluten Free, Non-GMO, Vegan, ...
(Date:10/12/2017)... Maryland (PRWEB) , ... October 12, 2017 , ... ... magnetic drug delivery system that we intend to develop to enable prevention of ... can lead to severe hearing loss, especially in pediatric patients. For cisplatin, hearing ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... , Oct. 2, 2017  Eli Lilly and Company ... results for the third quarter of 2017 on Tuesday, ... call on that day with the investment community and ... The conference call will begin at 9 a.m. ... access a live webcast of the conference call through ...
(Date:9/28/2017)... WASHINGTON , Sept. 28, 2017 Cohen ... to advance the use of wearable and home sensors ... brain disorders. Early Signal Foundation, a nonprofit organization focused ... populations, will provide an affordable analytical system to record ... ...
(Date:9/23/2017)... 2017 Janssen Biotech, Inc. (Janssen) announced today ... the U.S. Food and Drug Administration (FDA) for the ... the treatment of moderately to severely active rheumatoid arthritis ... are needed to further evaluate the safety of sirukumab ... "We are ...
Breaking Medicine Technology: